Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
Abstract
Background. Since universal vaccinations represents the most effective strategy to mitigate coronavirus disease 2019 (COVID-19), baseline assessment and post-vaccine monitoring of anti-SARS-CoV-2 neutralizing antibodies are essential to vaccination programs. Therefore, this study aimed to compare data of five commercial anti-SARS-CoV-2 immunoassays after administration of BNT162b2 mRNA Covid-19 vaccine.
Methods. Venous blood was collected from three healthcare workers, receiving a double (30 μg) dose of Comirnaty, on the day of the first vaccine dose and then at fixed intervals for the following 2 months. Anti-SARS-CoV-2 neutralizing antibody response was assayed with Roche Total Ig anti-RBD, DiaSorin IgG anti-S1/S2, Beckman Coulter IgG anti-RBD, SNIBE IgG anti-RBD and Technogenetics IgG anti-N/S1.
Results. A total number of 45 samples were drawn at the end of the 2-month study period. The Spearman’s correlations of absolute anti-SARS-CoV-2 antibodies were always excellent (all p<0.001), comprised between 0.967-0.994. Satisfactory results were also observed when absolute anti-SARS-CoV-2 antibodies values of the five methods were compared with the mean consensus value, with correlations always higher than 0.979 (all p<0.001). The agreement of anti-SARS-CoV-2 antibodies positivity versus the consensus median positivity ranged between 0.764 and 1.000 (always p<0.001), but become always >0.900 after readjustment of one assay cutoff.
Conclusion. All the immunoassays evaluated in this study appear suitable for monitoring anti-SARS-CoV-2 neutralizing antibodies response in subjects undergoing mRNA COVID-19 vaccination.
References
2. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. JAMA. 2021 Feb 26. doi: 10.1001/jama.2021.3199. Epub ahead of print.
3. Dolgin E. How COVID unlocked the power of RNA vaccines. Nature 2021;589:189-91.
4. Wu Z, Li T. Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives. Pharm Res. 2021 Mar 3:1–6. doi: 10.1007/s11095-021-03015-x. Epub ahead of print.
5. Topol EJ. Messenger RNA vaccines against SARS-CoV-2. Cell 2021;184:1401.
6. Koff WC, Berkley SF. A universal coronavirus vaccine. Science 2021;371:759.
7. Bohn MK, Loh TP, Wang CB, Mueller R, Koch D, Sethi S, et al. IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2. Clin Chem Lab Med 2020;58:2001-8.
8. Lippi G, Sciacovelli L, Trenti T, Plebani M. Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination. Clin Chem Lab Med. 2021 Jan 21. doi: 10.1515/cclm-2021-0038. Epub ahead of print.
9. Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. JAMA. 2021 Mar 19. doi: 10.1001/jama.2021.4388. Epub ahead of print.
10. Dye C, Mills MC. COVID-19 vaccination passports. Science 2021;371:1184.
11. Pegoraro M, Militello V, Salvagno GL, Gaino S, Bassi A, Caloi C, et al. Evaluation of three immunochromatographic tests in COVID-19 serologic diagnosis and their clinical usefulness. Eur J Clin Microbiol Infect Dis 2021;40:897-900.
12. Torjesen I. Covid-19 vaccine shortages: what is the cause and what are the implications? BMJ. 2021 Mar 19;372:n781.
13. Pimenta D, Yates C, Pagel C, Gurdasani D. Delaying the second dose of covid-19 vaccines. BMJ. 2021 Mar 18;372:n710.
14. Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet 2021;397:1057-8.
15. Saadat S, Tehrani ZR, Logue J, Newman M, Frieman MB, Harris AD, et al. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021 Mar 1:e213341. doi: 10.1001/jama.2021.3341. Epub ahead of print.
16. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021 Mar 10. doi: 10.1056/NEJMc2101667. Epub ahead of print.
17. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021 Feb 10. doi: 10.1038/s41586-021-03324-6. Epub ahead of print.
18. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol 2021;18:318-27.
19. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 2021;12:63.
20. Lippi G, Plebani M. SARS-CoV-2 antibodies titration: a reappraisal. Ann Transl Med 2020;8:1032.
Copyright (c) 2021 Elisa Danese, Martina Montagnana, Gian Luca Salvagno, Matteo Gelati, Denise Peserico, Laura Pighi, Simone De Nitto, Brandon M. Henry, Stefano Porru, Giuseppe Lippi
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.